A PHASE II TRIAL OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC WELL-DIFFERENTIATED DUODENO-PANCREATIC ENDOCRINE TUMORS (BETTER STUDY)

被引：0
|
作者：
Seitz, J. [1 ]
Smith, D. [2 ]
O'Toole, D. [3 ]
Lepere, C. [4 ]
Dromain, C. [5 ]
Gorana, A. [6 ]
Mitry, E. [7 ]
Ducreux, M. P. [8 ]
机构：
[1] Hop Enfants La Timone, Marseille, France
[2] Hop St Andre, Bordeaux, France
[3] Hop Beaujon, Clichy, France
[4] Hop Europeen Georges Pompidou, Paris, France
[5] Inst Gustave Roussy, Villejuif, France
[6] Labs Roche, Boulogne, France
[7] Inst Curie, Paris, France
[8] Inst Cancerol Gustave Roussy, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：378 / 378
页数：1
相关论文
共 50 条
  • [41] Simplified LV5FU2-irinotecan (FOLFIRI) in the first-line therapy of well-differentiated endocrine carcinomas of the duodeno- pancreatic area: Preliminary results of the FFCD 0302 phase II trial with GTE participation
    Cadiot, G.
    Bonnetain, F.
    Landi, B.
    Bouche, O.
    Mitry, E.
    Bedenne, L.
    Ruszniewski, P.
    Ricard, F.
    Vitry, F.
    Jouve, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] A Phase II Study to Evaluate the Safety and Efficacy of RAD001 plus Erlotinib in Patients with Well-Differentiated Neuroendocrine Tumors (NET)
    Bergsland, Emily
    Watt, Lindsey
    Ko, Andrew
    Tempero, Margaret
    Korn, W. Michael
    Kelley, Robin K.
    Weber, Tom
    Siah, Iche
    Hwang, Jimmy
    Nakakura, Eric
    Venook, Alan
    PANCREAS, 2012, 41 (02) : 342 - 343
  • [43] A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET)
    Bergsland, Emily K.
    Watt, Lindsey
    Ko, Andrew H.
    Tempero, Margaret A.
    Korn, Wolfgang Michael
    Kelley, Robin Katie
    Weber, Thomas
    Siah, Iche
    Hwang, Jimmy
    Nakakura, Eric K.
    Venook, Alan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [44] Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
    Yao, James C.
    Lombard-Bohas, Catherine
    Baudin, Eric
    Kvols, Larry K.
    Rougier, Philippe
    Ruszniewski, Philippe
    Hoosen, Sakina
    St Peter, Jessica
    Haas, Tomas
    Lebwohl, David
    Van Cutsem, Eric
    Kulke, Matthew H.
    Hobday, Timothy J.
    O'Dorisio, Thomas M.
    Shah, Manisha H.
    Cadiot, Guillaume
    Luppi, Gabriele
    Posey, James A.
    Wiedenmann, Bertram
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 69 - 76
  • [45] Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
    Pavel, M.
    Ruszniewski, P.
    Lombard-Bohas, C.
    Van Cutsem, E.
    Luppi, G.
    Rougier, P.
    Salazar, R.
    Hoosen, S.
    Cherfi, A.
    Yao, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 365 - 365
  • [46] Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial
    Yao, James C.
    Lombard-Bohas, Catherine
    Baudin, Eric
    Kvols, Larry K.
    Rougier, Philippe
    Ruszniewski, Philippe
    Hoosen, Sakina
    Peter, Jessica St.
    Haas, Tomas
    Lebwohl, David
    Van Cutsem, Eric
    Kulke, Matthew
    Hobday, Timothy J.
    O'Dorisio, Thomas M.
    Shah, Manisha H.
    Cadiot, Guillaume
    Luppi, Gabriele
    Posey, James A.
    Wiedenmann, Bertram
    PANCREAS, 2010, 39 (02) : 282 - 282
  • [47] Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
    Berruti, Alfredo
    Fazio, Nicola
    Ferrero, Anna
    Brizzi, Maria Pia
    Volante, Marco
    Nobili, Elisabetta
    Tozzi, Lucia
    Bodei, Lisa
    Torta, Mirella
    D'Avolio, Antonio
    Priola, Adriano Massimiliano
    Birocco, Nadia
    Amoroso, Vito
    Biasco, Guido
    Papotti, Mauro
    Dogliotti, Luigi
    BMC CANCER, 2014, 14
  • [48] Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
    Alfredo Berruti
    Nicola Fazio
    Anna Ferrero
    Maria Pia Brizzi
    Marco Volante
    Elisabetta Nobili
    Lucia Tozzi
    Lisa Bodei
    Mirella Torta
    Antonio D’Avolio
    Adriano Massimiliano Priola
    Nadia Birocco
    Vito Amoroso
    Guido Biasco
    Mauro Papotti
    Luigi Dogliotti
    BMC Cancer, 14
  • [49] A Prospective, Multi-Institutional Phase II Study of Pazopanib and Depot Octreotide in Advanced, Well-Differentiated Neuroendocrine Tumors
    Phan, Alexandria T.
    Halperin, Daniel M.
    Chan, Jennifer A.
    Fogelman, David R.
    Hess, Kenneth R.
    Malinowski, Paige
    Regan, Eileen
    Ng, Chaan S.
    Yao, James C.
    Kulke, Matthew H.
    PANCREAS, 2015, 44 (02) : 356 - 356
  • [50] Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer
    Propper, David
    Han, Haiyong
    Von Hoff, Daniel
    Borazanci, Erkut
    Reya, Tannishtha
    Ghergurovich, Jonathan
    Pshenichnaya, Irina
    Antal, Corina
    Condjella, Rachel
    Sharma, Shreya
    O'Dwyer, Peter
    Littlewood, Trevor
    Patel, Hitendra
    Saluja, Ashok
    Velagapudi, Mohana
    Yang, Lifeng
    Downes, Michael
    Evans, Ronald
    Evan, Gerard
    CANCER RESEARCH, 2019, 79 (13)
12345